A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Clinical trial NCT02711553 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02711553
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-19
- Primary completion
- 2018-02-16
- Enrollment
- 309
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.